{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:23:09Z","timestamp":1788340989890,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011501","name":"Qinghai Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2025-QY-253"],"award-info":[{"award-number":["2025-QY-253"]}],"id":[{"id":"10.13039\/501100011501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-64728-w","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:02:40Z","timestamp":1788339760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic review and network meta-analysis of first-line EGFR-TKI-based combination strategies for EGFR-mutant non-small cell lung cancer with brain metastases"],"prefix":"10.1038","volume":"16","author":[{"given":"Jiayun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-6179","authenticated-orcid":false,"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"64728_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J. Clin. 71, 209\u2013249. 2021\/02\/05 (2021).","journal-title":"Cancer J. Clin."},{"key":"64728_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/s0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai, A. A. et al. Lung cancer. Lancet 398, 535\u2013554. https:\/\/doi.org\/10.1016\/s0140-6736(21)00312-3 (2021). Review.","journal-title":"Lancet"},{"key":"64728_CR3","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang, Y. L. et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7, 78985\u201378993. 2016\/10\/16 (2016).","journal-title":"Oncotarget"},{"key":"64728_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi, Y. et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 9, 154\u2013162. 2014\/01\/15 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"64728_CR5","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","volume":"19","author":"SN Waqar","year":"2018","unstructured":"Waqar, S. N. et al. Non-small-cell Lung Cancer With Brain Metastasis at Presentation. Clin. Lung Cancer. 19, e373\u2013e379. 2018\/03\/13 (2018).","journal-title":"Clin. Lung Cancer"},{"key":"64728_CR6","doi-asserted-by":"publisher","unstructured":"Zhao, W. et al. Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer. Front. Oncol. 12 https:\/\/doi.org\/10.3389\/fonc.2022.912505 (2022).","DOI":"10.3389\/fonc.2022.912505"},{"key":"64728_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","volume":"88","author":"D Rangachari","year":"2015","unstructured":"Rangachari, D. et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 88, 108\u2013111. https:\/\/doi.org\/10.1016\/j.lungcan.2015.01.020 (2015). 2015\/02\/17.","journal-title":"Lung Cancer"},{"key":"64728_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00088","author":"J Remon","year":"2018","unstructured":"Remon, J. & Besse, B. Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2018.00088 (2018). 8.","journal-title":"Front. Oncol."},{"key":"64728_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10585-024-10276-4","volume":"41","author":"T Okuno","year":"2024","unstructured":"Okuno, T., Isobe, T. & Tsubata, Y. Current pharmacologic treatment of brain metastasis in non-small cell lung cancer. Clin. Exp. Metastasis. 41, 549\u2013565. https:\/\/doi.org\/10.1007\/s10585-024-10276-4 (2024). 2024\/03\/11.","journal-title":"Clin. Exp. Metastasis"},{"key":"64728_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown, P. D. et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. Jama 316, 401\u2013409. 2016\/07\/28 (2016).","journal-title":"Jama"},{"key":"64728_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","volume":"70","author":"Y Togashi","year":"2012","unstructured":"Togashi, Y. et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother. Pharmacol. 70, 399\u2013405. 2012\/07\/19 (2012).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"64728_CR12","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","volume":"18","author":"CS Gillespie","year":"2023","unstructured":"Gillespie, C. S. et al. Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis. J. Thorac. oncology: official publication Int. Association Study Lung Cancer. 18, 1703\u20131713. 2023\/07\/02 (2023).","journal-title":"J. Thorac. oncology: official publication Int. Association Study Lung Cancer"},{"key":"64728_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 378, 113\u2013125. 2017\/11\/21 (2018).","journal-title":"N. Engl. J. Med."},{"key":"64728_CR14","doi-asserted-by":"publisher","unstructured":"Reungwetwattana, T. et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology : Jco2018783118. (2018). 2018\/08\/29. https:\/\/doi.org\/10.1200\/jco.2018.78.3118.","DOI":"10.1200\/jco.2018.78.3118"},{"key":"64728_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/1759-7714.14783","volume":"14","author":"J Dai","year":"2023","unstructured":"Dai, J. et al. Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis. Thorac. Cancer. 14, 535\u2013543. 2023\/01\/04 (2023).","journal-title":"Thorac. Cancer"},{"key":"64728_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58\u201362. https:\/\/doi.org\/10.1126\/science.1104819 (2005). 2005\/01\/08.","journal-title":"Science"},{"key":"64728_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito, H. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 20, 625\u2013635. 2019\/04\/13 (2019).","journal-title":"Lancet Oncol."},{"key":"64728_CR18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","volume":"39","author":"Q Zhou","year":"2021","unstructured":"Zhou, Q. et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 39, 1279\u20131291e1273. 2021\/08\/14 (2021).","journal-title":"Cancer Cell."},{"key":"64728_CR19","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa, K. et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 1655\u20131669. 2019\/10\/09 (2019).","journal-title":"Lancet Oncol."},{"key":"64728_CR20","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard, D. et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N. Engl. J. Med. 389, 1935\u20131948. https:\/\/doi.org\/10.1056\/NEJMoa2306434 (2023). Article.","journal-title":"N. Engl. J. Med."},{"key":"64728_CR21","doi-asserted-by":"publisher","unstructured":"Lee, S. H. et al. Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: a Randomized, Double-blind, Exploratory Analysis From MARIPOSA. Journal Thorac. oncology 2025 J. article https:\/\/doi.org\/10.1016\/j.jtho.2025.06.030","DOI":"10.1016\/j.jtho.2025.06.030"},{"key":"64728_CR22","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.26355\/eurrev_202110_26993","volume":"25","author":"HJ Lee","year":"2021","unstructured":"Lee, H. J. et al. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. Eur. Rev. Med. Pharmacol. Sci. 25, 6232\u20136244. https:\/\/doi.org\/10.26355\/eurrev_202110_26993 (2021). 2021\/11\/04.","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"64728_CR23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12885-021-08291-9","volume":"21","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting. BMC Cancer. 21, 602. 2021\/05\/27 (2021).","journal-title":"BMC Cancer"},{"key":"64728_CR24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1186\/s12885-022-10391-z","volume":"22","author":"K Shang","year":"2022","unstructured":"Shang, K. et al. Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR\/TP53 co-mutation. BMC Cancer. 22, 1295. 2022\/12\/13 (2022).","journal-title":"BMC Cancer"},{"key":"64728_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","volume":"38","author":"V Noronha","year":"2020","unstructured":"Noronha, V. et al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J. Clin. Oncol. 38, 124\u2013136. 2019\/08\/15 (2020).","journal-title":"J. Clin. Oncol."},{"key":"64728_CR26","unstructured":"Lu, S. et al. Aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations (AENEAS2) Free. In: Cancer Research 2025, AMER Assoc Cancer Research 615 Chestnut St, 17th Floor, Philadelphia, PA &#8230."},{"key":"64728_CR27","doi-asserted-by":"publisher","first-page":"20952","DOI":"10.1038\/s41598-025-03422-9","volume":"15","author":"J Li","year":"2025","unstructured":"Li, J. et al. Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study. Sci. Rep. 15, 20952. 2025\/07\/02 (2025).","journal-title":"Sci. Rep."},{"key":"64728_CR28","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1158\/1078-0432.Ccr-24-3532","volume":"31","author":"S Kanda","year":"2025","unstructured":"Kanda, S. et al. Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation. Clin. Cancer Res. 31, 2317\u20132326. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-3532 (2025). 2025\/03\/31 21.","journal-title":"Clin. Cancer Res."},{"key":"64728_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.23.02219","volume":"42","author":"PA J\u00e4nne","year":"2024","unstructured":"J\u00e4nne, P. A. et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 42, 808\u2013820. 2023\/12\/03 (2024).","journal-title":"J. Clin. Oncol."},{"key":"64728_CR30","doi-asserted-by":"publisher","first-page":"e2255050","DOI":"10.1001\/jamanetworkopen.2022.55050","volume":"6","author":"X Hou","year":"2023","unstructured":"Hou, X. et al. Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study. JAMA Netw. Open. 6, e2255050. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55050 (2023). 2023\/02\/09.","journal-title":"JAMA Netw. Open."},{"key":"64728_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi, Y. et al. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J. Clin. Oncol. 38, 115\u2013123. 2019\/11\/05 (2020).","journal-title":"J. Clin. Oncol."},{"key":"64728_CR32","doi-asserted-by":"publisher","unstructured":"Shi, H. et al. Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial. Thorac Cancer; 16: e70137. 2025\/08\/11. (2025). https:\/\/doi.org\/10.1111\/1759-7714.70137","DOI":"10.1111\/1759-7714.70137"},{"key":"64728_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-024-01927-9","volume":"9","author":"HQ Zhou","year":"2024","unstructured":"Zhou, H. Q. et al. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial. Signal. Transduct. Target. Ther. 9, 215. 2024\/08\/13 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"64728_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.24.00533","volume":"43","author":"X Le","year":"2025","unstructured":"Le, X. et al. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Na\u00efve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J. Clin. Oncol. 43, 403\u2013411. 2024\/10\/08 22:18 (2025).","journal-title":"J. Clin. Oncol."},{"key":"64728_CR35","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","volume":"17","author":"H Kenmotsu","year":"2022","unstructured":"Kenmotsu, H. et al. Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study. J. Thorac. oncology: official publication Int. Association Study Lung Cancer. 17, 1098\u20131108. 2022\/06\/01 (2022).","journal-title":"J. Thorac. oncology: official publication Int. Association Study Lung Cancer"},{"key":"64728_CR36","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1038\/s41598-022-08449-w","volume":"12","author":"TH Chiu","year":"2022","unstructured":"Chiu, T. H. et al. The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis. Sci. Rep. 12, 4398. 2022\/03\/17 (2022).","journal-title":"Sci. Rep."},{"key":"64728_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2019.08.021","volume":"121","author":"T Jiang","year":"2019","unstructured":"Jiang, T. et al. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases. Eur. J. Cancer. 121, 98\u2013108. 2019\/10\/01 (2019).","journal-title":"Eur. J. Cancer"},{"key":"64728_CR38","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jamaoncol.2019.1847","volume":"5","author":"TE Stinchcombe","year":"2019","unstructured":"Stinchcombe, T. E. et al. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 5, 1448\u20131455. 2019\/08\/09 (2019).","journal-title":"JAMA Oncol."},{"key":"64728_CR39","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","volume":"16","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). J. Thorac. oncology: official publication Int. Association Study Lung Cancer. 16, 1533\u20131546. 2021\/05\/26 (2021).","journal-title":"J. Thorac. oncology: official publication Int. Association Study Lung Cancer"},{"key":"64728_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cncr.34553","volume":"129","author":"Y Lee","year":"2023","unstructured":"Lee, Y. et al. A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation. Cancer 129, 405\u2013414. https:\/\/doi.org\/10.1002\/cncr.34553 (2023). 2022\/12\/02.","journal-title":"Cancer"},{"key":"64728_CR41","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/cas.13079","volume":"107","author":"Y Chen","year":"2016","unstructured":"Chen, Y. et al. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma. Cancer Sci. 107, 1800\u20131805. https:\/\/doi.org\/10.1111\/cas.13079 (2016). 2016\/09\/15.","journal-title":"Cancer Sci."},{"key":"64728_CR42","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2016.05.013","volume":"11","author":"T Jiang","year":"2016","unstructured":"Jiang, T. et al. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases. J. Thorac. oncology: official publication Int. Association Study Lung Cancer. 11, 1718\u20131728. 2016\/05\/31 (2016).","journal-title":"J. Thorac. oncology: official publication Int. Association Study Lung Cancer"},{"key":"64728_CR43","doi-asserted-by":"publisher","unstructured":"Byeon, S. et al. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Medical oncology (Northwood, London, England); 33: 97. (2016). 2016\/07\/23. https:\/\/doi.org\/10.1007\/s12032-016-0811-3.","DOI":"10.1007\/s12032-016-0811-3"},{"key":"64728_CR44","doi-asserted-by":"publisher","first-page":"13304","DOI":"10.18632\/oncotarget.14515","volume":"8","author":"Q Zhu","year":"2017","unstructured":"Zhu, Q. et al. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). Oncotarget 8, 13304\u201313311. https:\/\/doi.org\/10.18632\/oncotarget.14515 (2017). 2017\/01\/12.","journal-title":"Oncotarget"},{"key":"64728_CR45","doi-asserted-by":"publisher","first-page":"111309","DOI":"10.18632\/oncotarget.22785","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score. Oncotarget 8, 111309\u2013111317. https:\/\/doi.org\/10.18632\/oncotarget.22785 (2017). 2018\/01\/18.","journal-title":"Oncotarget"},{"key":"64728_CR46","doi-asserted-by":"publisher","first-page":"45193","DOI":"10.1038\/srep45193","volume":"7","author":"Y Fan","year":"2017","unstructured":"Fan, Y. et al. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases. Sci. Rep. 7, 45193. 2017\/03\/24 (2017).","journal-title":"Sci. Rep."},{"key":"64728_CR47","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","volume":"35","author":"WJ Magnuson","year":"2017","unstructured":"Magnuson, W. J. et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Na\u00efve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. J. Clin. oncology: official J. Am. Soc. Clin. Oncol. 35, 1070\u20131077. 2017\/01\/24 (2017).","journal-title":"J. Clin. oncology: official J. Am. Soc. Clin. Oncol."},{"key":"64728_CR48","first-page":"421","volume":"33","author":"M Yu","year":"2018","unstructured":"Yu, M. et al. Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. Cancer Biother. Radiopharm. 33, 421\u2013426. 2019\/05\/06 (2018).","journal-title":"Cancer Biother. Radiopharm."},{"key":"64728_CR49","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s11596-018-1984-0","volume":"38","author":"S Ke","year":"2018","unstructured":"Ke, S. et al. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases. Curr. Med. Sci. 38, 1062\u20131068. https:\/\/doi.org\/10.1007\/s11596-018-1984-0 (2018). Article.","journal-title":"Curr. Med. Sci."},{"key":"64728_CR50","doi-asserted-by":"publisher","unstructured":"Chen, H. et al. Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis. Medicine (Baltimore); 97: e13014. 2018\/11\/02. (2018). https:\/\/doi.org\/10.1097\/md.0000000000013014","DOI":"10.1097\/md.0000000000013014"},{"key":"64728_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/14737140.2018.1409623","volume":"18","author":"SH Li","year":"2018","unstructured":"Li, S. H. et al. Response to afatinib in treatment-na\u00efve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert Rev. Anticancer Ther. 18, 81\u201389. 2017\/11\/28 (2018).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"64728_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-018-2861-1","volume":"139","author":"S Sung","year":"2018","unstructured":"Sung, S. et al. Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer. J. Neurooncol. 139, 205\u2013213. 2018\/04\/13 (2018).","journal-title":"J. Neurooncol"},{"key":"64728_CR53","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.5114\/aoms.2018.78939","volume":"14","author":"W Wang","year":"2018","unstructured":"Wang, W., Song, Z. & Zhang, Y. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis. Archives Med. science: AMS. 14, 1298\u20131307. 2018\/11\/06 (2018).","journal-title":"Archives Med. science: AMS"},{"key":"64728_CR54","doi-asserted-by":"publisher","unstructured":"Chen, Y. et al. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis. BMC CANCER. 19. Article. https:\/\/doi.org\/10.1186\/s12885-019-6005-6 (2019).","DOI":"10.1186\/s12885-019-6005-6"},{"key":"64728_CR55","doi-asserted-by":"publisher","first-page":"e1417","DOI":"10.1634\/theoncologist.2019-0152","volume":"24","author":"JH Lee","year":"2019","unstructured":"Lee, J. H. et al. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. Oncologist 24, e1417\u2013e1425. 2019\/05\/28 (2019).","journal-title":"Oncologist"},{"key":"64728_CR56","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.7150\/jca.30131","volume":"10","author":"C Wang","year":"2019","unstructured":"Wang, C. et al. The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. J. Cancer. 10, 1985\u20131990. https:\/\/doi.org\/10.7150\/jca.30131 (2019). Article.","journal-title":"J. Cancer"},{"key":"64728_CR57","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/1759-7714.13189","volume":"10","author":"Y Saida","year":"2019","unstructured":"Saida, Y. et al. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases. Thorac. Cancer. 10, 2106\u20132116. 2019\/09\/12 (2019).","journal-title":"Thorac. Cancer"},{"key":"64728_CR58","doi-asserted-by":"publisher","first-page":"8311","DOI":"10.2147\/OTT.S223216","volume":"12","author":"N An","year":"2019","unstructured":"An, N. et al. Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study. Onco Targets Ther. 12, 8311\u20138318. 2019\/10\/22 (2019).","journal-title":"Onco Targets Ther."},{"key":"64728_CR59","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2147\/cmar.S184922","volume":"11","author":"ZY He","year":"2019","unstructured":"He, Z. Y. et al. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. Cancer Manag Res. 11, 2129\u20132138. https:\/\/doi.org\/10.2147\/cmar.S184922 (2019). 2019\/04\/03.","journal-title":"Cancer Manag Res."},{"key":"64728_CR60","doi-asserted-by":"publisher","first-page":"923","DOI":"10.21873\/anticanres.13195","volume":"39","author":"K Saruwatari","year":"2019","unstructured":"Saruwatari, K. et al. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases. Anticancer Res. 39, 923\u2013931. 2019\/02\/04 (2019).","journal-title":"Anticancer Res."},{"key":"64728_CR61","doi-asserted-by":"publisher","first-page":"e0231546","DOI":"10.1371\/journal.pone.0231546","volume":"15","author":"DG Hyun","year":"2020","unstructured":"Hyun, D. G. et al. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis. PLoS One. 15, e0231546. 2020\/04\/17 (2020).","journal-title":"PLoS One"},{"key":"64728_CR62","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1111\/1759-7714.14169","volume":"12","author":"Y Gu","year":"2021","unstructured":"Gu, Y. et al. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique. Thorac. CANCER. 12, 3157\u20133168. https:\/\/doi.org\/10.1111\/1759-7714.14169 (2021). Article.","journal-title":"Thorac. CANCER"},{"key":"64728_CR63","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study. Technol. Cancer Res. Treat. 20. Article. https:\/\/doi.org\/10.1177\/1533033821997819 (2021).","DOI":"10.1177\/1533033821997819"},{"key":"64728_CR64","doi-asserted-by":"publisher","unstructured":"Lee, C. K. et al. Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trials. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer (2026). 2026\/01\/15 https:\/\/doi.org\/10.1016\/j.jtho.2026.01.001","DOI":"10.1016\/j.jtho.2026.01.001"},{"key":"64728_CR65","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3171\/2021.9.JNS211373","volume":"137","author":"GY Chiou","year":"2022","unstructured":"Chiou, G. Y. et al. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases. J. Neurosurg. 137, 563\u2013570. 2021\/12\/18 (2022).","journal-title":"J. Neurosurg."},{"key":"64728_CR66","doi-asserted-by":"publisher","first-page":"1259880","DOI":"10.3389\/fonc.2023.1259880","volume":"13","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases. Front. Oncol. 13, 1259880. 2024\/02\/05 (2023).","journal-title":"Front. Oncol."},{"key":"64728_CR67","doi-asserted-by":"publisher","unstructured":"Hasan, N. & Nagasaka, M. Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer. Expert Rev. Respir Med 2025: 1 -10.2025\/02\/19. https:\/\/doi.org\/10.1080\/17476348.2025.2467338.","DOI":"10.1080\/17476348.2025.2467338"},{"key":"64728_CR68","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho, B. C. et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N. Engl. J. Med. 391, 1486\u20131498. 2024\/06\/26 (2024).","journal-title":"N. Engl. J. Med."},{"key":"64728_CR69","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1186\/s12885-024-13363-7","volume":"24","author":"G Deng","year":"2024","unstructured":"Deng, G. et al. Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases. BMC Cancer. 24, 1571. https:\/\/doi.org\/10.1186\/s12885-024-13363-7 (2024). 2024\/12\/24.","journal-title":"BMC Cancer"},{"key":"64728_CR70","doi-asserted-by":"publisher","first-page":"e078335","DOI":"10.1136\/bmjopen-2023-078335","volume":"14","author":"KP Robledo","year":"2024","unstructured":"Robledo, K. P. et al. Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration. BMJ Open. 14, e078335. 2024\/07\/06 (2024).","journal-title":"BMJ Open."},{"key":"64728_CR71","doi-asserted-by":"publisher","first-page":"22901","DOI":"10.1038\/s41598-024-74496-0","volume":"14","author":"J Ma","year":"2024","unstructured":"Ma, J. et al. First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Sci. Rep. 14, 22901. 2024\/10\/03 (2024).","journal-title":"Sci. Rep."},{"key":"64728_CR72","doi-asserted-by":"publisher","first-page":"739765","DOI":"10.3389\/fonc.2021.739765","volume":"11","author":"S Taslimi","year":"2021","unstructured":"Taslimi, S. et al. Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation\/ALK Rearrangement: A Systematic Review and Network Meta-Analysis. Front. Oncol. 11, 739765. 2021\/12\/25 (2021).","journal-title":"Front. Oncol."},{"key":"64728_CR73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer. 20, 26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x (2020). 2019\/10\/12.","journal-title":"Nat. Rev. Cancer"},{"key":"64728_CR74","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","volume":"15","author":"GN Naumov","year":"2009","unstructured":"Naumov, G. N. et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 15, 3484\u20133494. 2009\/05\/19 (2009).","journal-title":"Clin. Cancer Res."},{"key":"64728_CR75","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262\u2013269. 2016\/02\/02 (2016).","journal-title":"Nat. Med."},{"key":"64728_CR76","doi-asserted-by":"publisher","unstructured":"Clarke, J. L. et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol; 99: 283\u2013286. 2010\/02\/11. (2010). https:\/\/doi.org\/10.1007\/s11060-010-0128-6","DOI":"10.1007\/s11060-010-0128-6"},{"key":"64728_CR77","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1186\/s12885-019-6005-6","volume":"19","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis. BMC Cancer. 19, 793. 2019\/08\/11 (2019).","journal-title":"BMC Cancer"},{"key":"64728_CR78","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1158\/0008-5472.Can-04-3547","volume":"65","author":"P Chinnaiyan","year":"2005","unstructured":"Chinnaiyan, P. et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 65, 3328\u20133335. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-3547 (2005). 2005\/04\/19.","journal-title":"Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64728-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:02:42Z","timestamp":1788339762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64728-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["64728"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-64728-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26818"}}